Drugs / Systane Complete
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06886373 | Mar 2025 → Dec 2027 expected | — | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06763731 | May 2024 → Jan 2027 expected | — | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04230720 | Apr → Dec 2021 | cataract | Weill Medical College of Cornell University | Withdrawn | No outcome recorded |
| Phase 4 | NCT04091581 | Nov 2019 → Feb 2020 | dry eye syndrome | University of Waterloo | Completed | No outcome recorded |
| Phase 4 | NCT03848221 | May → Oct 2019 | contact lens corneal edema, dry eye syndrome | University of Alabama at Birmingham | Completed | Missed primary |
| Phase 4 | NCT03682809 | Nov 2018 → Mar 2019 | dry eye syndrome | University of Alabama at Birmingham | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-01-12 | Alcon Research | Alcon Announces Launch of Systane Complete Preservative-Free Lubricant Eye Drops in Europe alcon.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Systane Complete | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04230720 ↗ |
| Modality | Other / unclassified | “Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.” NCT03682809 ↗ |
| Route | Topical | “Systane COMPLETE MD1 bottle will be prescribed to all subjects who signed the ICF, with a dosing frequency of 1-2 drops q.i.d OU for 1-2 month.” NCT06763731 ↗ |